FoundationOne CDx (F1CDx)

The FDA on November 30, 2017, granted marketing approval to the FoundationOne CDx, a Next Generation Sequencing (NGS) based in vitro diagnostic (IVD) to detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type. The test can also identify which patients with Non-Small Cell Lung Cancer (NSCLC), melanoma, breast cancer, colorectal cancer, or ovarian cancer may benefit from 15 different FDA-approved targeted treatment options. This test is offered by Foundation Medicine, Inc.